This is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer.
The contract has a ceiling value of $6,073,473,460 and an ultimate completion date of August 31, 2025. It is a multiple award FSS contract under the Pharmaceuticals and Drugs category (FSS-61-IB), enabling the VA and other federal agencies to procure a wide range of pharmaceutical products and services from Merck as needed. The contract does not have a set-aside designation. Through this contract, Merck provides critical vaccines, drugs, and medical countermeasures to support various government healthcare programs and public health initiatives, including those administered by the Department of Defense, Department of Health and Human Services, and Centers for Disease Control and Prevention. Key products supplied under this contract include vaccines such as MMR, varicella, hepatitis, pneumococcal, and COVID-19 antivirals like molnupiravir, as well as cancer treatments like Welireg (belzutifan). Merck also holds several high-value Indefinite Delivery Vehicles (IDVs) with the CDC for vaccine supply and storage services, valued up to $4 billion, and a Blanket Purchase Agreement with the VA for Welireg, valued at $15 million. These contracting vehicles provide federal agencies with flexible, long-term access to essential pharmaceutical products and services.
Generated 2/16/25, 12:03 AM